Disease · EFO_1001827
post-concussion syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. post-concussion syndrome. Diseases, record EFO_1001827. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001827
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OXYGEN | CHEMBL1234886 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets |
| QUETIAPINE FUMARATE | CHEMBL3188993 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METOCLOPRAMIDE | CHEMBL86 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 2 | Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 1 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 1 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| HTR3A | 5-hydroxytryptamine receptor 3A | 1 | Serotonin 3a (5-HT3a) receptor antagonist | Unknown | https://conductscience.org/library/genes/3359 | Drugs and targets |
| HTR4 | 5-hydroxytryptamine receptor 4 | 1 | Serotonin 4 (5-HT4) receptor agonist | Unknown | https://conductscience.org/library/genes/3360 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 1 | Serotonin transporter inhibitor | Unknown | https://conductscience.org/library/genes/6532 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01306968 | Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI) | Phase 2 | 79 | 2014-09-05 | Post-concussive Symptoms, Traumatic Brain Injury | OXYGEN | Its record names the disease | ClinicalTrials.gov |
| NCT01611194 | mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms | Phase 2 | 71 | 2018-11-21 | Traumatic Brain Injury With Brief Loss of Consciousness, Post-Concussion Syndrome | OXYGEN | Its record names the disease | ClinicalTrials.gov |
| NCT06333990 | Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) | Phase 3 | 146 | Mild Traumatic Brain Injury | QUETIAPINE FUMARATE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00208585 | Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury | Not applicable | 100 | Traumatic Brain Injury | SERTRALINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02089594 | Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS) | Phase 3 | 59 | Post-Concussion Syndrome, Traumatic Brain Injury | OXYGEN | Its record names the disease | ClinicalTrials.gov | |
| NCT00237705 | Intravenous Metoclopramide for the Treatment of Post Concussive Headache: a Randomized Placebo Controlled Trial | Not applicable | 40 | Post Concussive Headache, Post Concussive Syndrome | METOCLOPRAMIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06665633 | Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy | Phase 1 | 40 | Mild Traumatic Brain Injury, Hyperbaric Oxygen Therapy, Depression | OXYGEN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| HBO2 at 1.5 Atomspheres Absolute (ATA) vs Sham Control (1.2 Atomspheres): deaths from any cause | 0 of 36 | 0 of 35 | 71 | NCT01611194 | Trial comparisons |
| HBO2 at 1.5 Atomspheres Absolute (ATA) vs Sham Control (1.2 Atomspheres): serious adverse events | 5 of 36 | 3 of 35 | 71 | NCT01611194 | Trial comparisons |
Papers from its trials15
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 32189664 | DERIVED | 1 | PubMed |
| 31394603 | DERIVED | 2 | PubMed |
| 31394602 | DERIVED | 2 | PubMed |
| 31394601 | DERIVED | 1 | PubMed |
| 31394600 | DERIVED | 1 | PubMed |
| 30099354 | DERIVED | 1 | PubMed |
| 30098189 | DERIVED | 1 | PubMed |
| 28771392 | DERIVED | 1 | PubMed |
| 28768075 | DERIVED | 1 | PubMed |
| 28768073 | DERIVED | 1 | PubMed |
1 to 10 of 15
See all 15 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001827
GET https://conductscience.org/api/diseases/v1/EFO_1001827/drugs